Please assess the completion status of the following clinical trial:

Trial Title: Reducing Involuntary Movements in Participants With Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of using a dopamine receptor antagonist for at least 3 months~* Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening~* Participant has successfully completed a controlled study of SD-809 for treatment of moderate to severe tardive dyskinesia~* Participants with underlying psychiatric diagnosis are stable and have no change in psychoactive medications~* Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months~* History of being compliant with prescribed medications~* Able to swallow study drug whole~* Be in good general health and is expected to attend all study visits and complete study assessments~* Female participants must not be pregnant and agree to an acceptable method of contraception~Exclusion Criteria:~* Currently receiving medication for the treatment of tardive dyskinesia~* Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias~* Have a serious untreated or undertreated psychiatric illness~* Have recent history or presence of violent behavior~* Have unstable or serious medical illness~* Have evidence of hepatic impairment~* Have evidence of renal impairment~* Have known allergy to any component of SD-809 or tetrabenazine~* Has participated in an investigational drug or device trial (other than Study C-18, Study C-23, or any other eligible TEV-50717 parent study) and received study drug within 30 days~* Have acknowledged use of illicit drugs~* Have a history of alcohol or substance abuse in the previous 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: SD-809 (Type: EXPERIMENTAL): Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
- Part B: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
- Part B: SD-809 (Type: ACTIVE_COMPARATOR): Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
- Part C: SD-809 (Type: EXPERIMENTAL): EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.

Based on this trial design, predict the completion outcome and termination type (if applicable).